Metabolic Syndrome: Current Issues of Diagnosis, Epidemiology and Prevention Worldwide and in the Russian Federation
https://doi.org/10.31631/2073-30462025-24-4-95-105
Abstract
The prevalence of metabolic syndrome, following the prevalence of obesity is increasing all over the world. However, the lack of standardized diagnostic criteria makes it difficult to assess the epidemiological patterns of it. The development of preventive measures for this condition will prevent the development of pathologies that are the leading causes of mortality worldwide. Objective. To highlight modern aspects of diagnosis, epidemiology, risk factors, existing and perspective directions of the prevention of metabolic syndrome in the world and in the Russian Federation, according to the scientific literature. Results. The increasing prevalence of obesity and metabolic syndrome is observed in different countries of the world. Taking into account both individual and population risk factors, that are described in the literature for today, it is necessary to include the principles of personalized medicine in the prevention strategies of this condition. Conclusions. A multidisciplinary approach to the problem of metabolic syndrome will not only improve the detection and diagnosis of this condition, but also apply preventive measures in the risk groups, which can be identified using epidemiological methods of gathering and processing information.
About the Author
A. G. Сhigir
Sechenov University
Russian Federation
Russian Federation
Alexandra G. Сhigir – postgraduate student of the department of epidemiology and evidence based medicine
Moscow
References
1. Clinical recommendations for the management of patients with metabolic syndrome. Ministry of Health of the Russian Federation. Approved by the Russian Medical Society for Arterial Hypertension and the Profile Commission for Cardiology.2013. Available at: https://www.gipertonik.ru/clinical_recommendations. Accessed: 16 Jan 2025. (In Russ).
2. Vesikansa A, Mehtälä J, Mutanen K, et al. The association between body mass index groups and metabolic comorbidities with healthcare and medication costs: a nation-wide biobank and registry study in Finland. Journal of Market Access & Health Policy. 2023;11(1):2166313. doi: 10.1080/20016689.2023.2166313
3. Le Roux CW, Chubb B, Nørtoft E, et al. Obesity and healthcare resource utilization: results from Clinical Practice Research Database (CPRD). Obesity Science & Practice. 2018;4(5):409–416. doi: 10.1002/osp4.291
4. Balanova YuA, Drapkina OM, Kutsenko VA, и др. Obesity in the Russian population during the COVID-19 pandemic and associated factors. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3793. (In Russ). doi: 10.15829/1728-8800-2023-3793
5. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Health Organization; Geneva, Switzerland: 2013. ISBN: 978-92-4-150623-6
6. Dedov II, Mel’nishenko GA, Butrova SA. Zhirovaya tkan’ kak endokrinnyy organ. Obesity and metabolism. 2006;3(1):6–13. (In Russ). doi: 10.14341/2071-8713-4937
7. Butrova SA, Dzgoeva FKh. Vistseral’noe ozhirenie - klyuchevoe zvenometabolicheskogo sindroma. Obesity and metabolism. 2004;1(1):10-16. (In Russ). doi: 10.14341/2071-8713-5173
8. Ford ES, Giles WH, Mokdad AH. Increasing Prevalence of the Metabolic Syndrome Among U.S. Adults. Diabetes Care. 2004;27(10): 2444–2449. doi: 10.2337/diacare.27.10.2444
9. Dattani S, Spooner F, Ritchie H, et al. (2023) - “Causes of Death” Published online at OurWorldinData.org. Available at: https://ourworldindata.org/causes-of-death. Accessed 16 Jan 2025.
10. Anikin DA., Solovyeva IA, Demko IV, et al. Free-radical oxidation as a pathogenetic factor of metabolic syndrome. Obesity and metabolism. 2022;19(3):306–316. (In Russ). doi: 10.14341/omet12804
11. Uchamprina VA, Romantsova TI, Kalashnikov MF. Metabolic syndrome: аrguments pro’s and con’s. Obesity and metabolism. 2012;9(2):17–27. (In Russ). doi: 10.14341/omet2012217-27
12. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 2018;37(12):1595–1607. doi: 10.2337/diab.37.12.1595
13. Sosnova EA. Metabolic syndrome. V.F. Snegirev Archives of Obstetrics and Gynecology, Russian journal. 2016; 3(4): 172–180. (In Russ). doi: 10.18821/2313-8726-2016-3-4-172-180
14. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine. 1989;149(7):1514–1520. doi:10.1001/archinte.149.7.1514
15. Simmons RK, Alberti KG, Gale EA, et al. The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia. 2010;53(4):600–605. doi:10.1007/s00125-009-1620-4
16. Hai AA, Iftikhar S, Latif S, et al. Prevalence of Metabolic Syndrome in Overweight and Obese Patients and Their Measurement of Neck Circumference: A Cross-sectional Study. Cureus. 2019;11(11):e6114. doi: 10.7759/cureus.6114
17. Hingorjo MR, Zehra S, Imran E, et al. Neck circumference: A supplemental tool for the diagnosis of metabolic syndrome. Journal of the Pakistan Medical Association. 2016;66(10):1221–1226.
18. Valencia-Sosa E, González-Pérez GJ, Chávez-Palencia C, et al. Neck Circumference as a Valuable Tool to Identify the Risk of Metabolic Syndrome in Mexican Children. Children (Basel). 2024;11(8):908. doi: 10.3390/children11080908
19. Ren C, Zhang X, Zhu Y, et al. Low calf circumference can predict nutritional risk and mortality in adults with metabolic syndrome aged over 80 years. BMC Endocrine Disorders. 2022;22(1):47. doi: 10.1186/s12902-022-00964-1
20. Kytikova OY, Antonyuk MV, Kantur TA, et al. Prevalence and biomarkers in metabolic syndrome. Obesity and metabolism. 2021;18(3):302–312. (In Russ). doi: 10.14341/omet12704
21. Adil SO, Islam MA, Musa KI, et al. Prevalence of Metabolic Syndrome among Apparently Healthy Adult Population in Pakistan: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2023;11(4):531. doi:10.3390/healthcare11040531
22. De Siqueira Valadares LT, de Souza LSB, Salgado Júnior VA, et al. Prevalence of metabolic syndrome in Brazilian adults in the last 10 years: a systematic review and meta-analysis. BMC Public Health. 2022;22(1):327. doi:10.1186/s12889-022-12753-5
23. Popkin BM, Corvalan C, Grummer-Strawn LM. Dynamics of the double burden of malnutrition and the changing nutrition reality. The Lancet. 2020;395(10217):65–74. doi:10.1016/S0140-6736(19)32497-3
24. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet. 2024;403(10431):1027–1050. doi:10.1016/S0140-6736(23)02750-2
25. Xiao J, Wu CL, Gao YX, et al. Prevalence of metabolic syndrome and its risk factors among rural adults in Nantong, China. Scientific Reports. 2016;6:38089. doi:10.1038/srep38089
26. Park D, Shin MJ, Després JP, et al. 20-Year Trends in Metabolic Syndrome Among Korean Adults From 2001 to 2020. JACC: Asia. 2023;3(3):491–502. doi:10.1016/j.jacasi.2023.02.007
27. Ranasinghe P, Mathangasinghe Y, Jayawardena R, et al. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(1):101. doi:10.1186/s12889-017-4041-1
28. Bikbov MM, Kazakbaeva GM, Gilmanshin TR, et al. Prevalence of metabolic syndrome in a Russian population: The Ural Eye and Medical Study and the Ural Very Old Study. Metabolism Open. 2022;14:100183. doi:10.1016/j.metop.2022.100183
29. Grinshtein YuI, Shabalin VV, Ruf RR, et al. The prevalence of metabolic syndrome in the Krasnoyarsk Krai population and the features of its association with hyperuricemia. Russian Journal of Cardiology. 2020;25(6):3852. (In Russ). doi: 10.15829/1560-4071-2020-3852
30. Alferova VI, Mustafina SV. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obesity and metabolism. 2022;19(1):96-105. (In Russ). doi: 10.14341/omet12809
31. Balanova YuA, Shalnova SA, Deev AD, et al. OBESITY IN RUSSIAN POPULATION — PREVALENCE AND ASSOCIATION WITH THE NON-COMMUNICABLE DISEASES RISK FACTORS. Russian Journal of Cardiology. 2018;(6):123–130. (In Russ). doi: 10.15829/1560-4071-2018-6-123-130
32. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ). doi: 10.15829/1728-8800-2022-3235
33. Moore JX, Chaudhary N, Akinyemiju T. Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012. Preventing Chronic Disease. 2017;14:E24. doi: 10.5888/pcd14.160287
34. Ivanova EG, Fomin IV. Arterial hypertension and metabolic syndrome in non-indigenous residents of the Far North. The Russian Journal of Preventive Medicine. 2022; 25(9):46–52. (In Russ). doi:10.17116/profmed20222509146
35. Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. Nature Reviews Methods Primers. 2021;1:59. doi:10.1038/s43586-021-00056-9
36. Antontseva EV, Degtyareva AO, Korbolina EE, et al. Human-genome single nucleotide polymorphisms affecting transcription factor binding and their role in pathogenesis. Vavilovskii zhurnal genetiki i selektsii. 2023;27(6):662–675. (In Russ). doi:10.18699/VJGB-23-77
37. Wang Q, Ren D, Bi Y, et al. Association and functional study between ADIPOQ and metabolic syndrome in elderly Chinese Han population. Aging (Albany NY). 2020;12(24):25819–25827. doi:10.18632/aging.104203
38. Pogozheva AV, Sorokina EYu. Association of rs266729 and rs16861194 polymorphisms of the ADIPOQ gene with the risk of obesity in residents of the Moscow region. Alma- nac of Clinical Medicine. 2021; 49 (5): 315–322. (In Russ). doi:10.18786/2072-0505-2021-49-038
39. Smetnev SA, Meshkov AN, Klimushina MV, et al. ASSOCIATION OF THE VARIANTS OF NUCLEOTIDE SEQUENCE OF THE GENE ADIPOQ WITH PLASMATIC LEVEL OF ADIPO-NECTIN, THE GRADE OF CORONARY ATHEROSCLEROSIS SEVERITY AND RATE OF CARDIOVASCULAR DISEASES. Russian Journal of Cardiology. 2018;(8):25–31. (In Russ). doi:10.15829/1560-4071-2018-8-25-31
40. Choi SW, Mak TS, O’Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nature Protocols. 2020;15(9):2759–2772. doi:10.1038/s41596-020-0353-1
41. Kucher AN. The FTO Gene and Diseases: The Role of Genetic Polymorphism, Epigenetic Modifications, and Environmental Factors. Russian Journal of Genetics. 2020;56(9):985–1005. (In Russ). doi:10.31857/S0016675820090131
42. Scuteri A, Sanna S, Chen WM, et al. Genome-Wide Association Scan Shows Genetic Variants in the FTO Gene Are Associated with Obesity-Related Traits. PLOS Genetics. 2007;3(7):e115. doi:10.1371/journal.pgen.0030115
43. Hardy DS, Racette SB, Hoelscher DM. Macronutrient Intake as a Mediator with FTO to Increase Body Mass Index. Journal of the American College of Nutrition. 2014;33(4):256–266. doi:10.1080/07315724.2013.879458
44. Hardy DS, Garvin JT, Mersha TB, et al. Ancestry specific associations of FTO gene variant and metabolic syndrome: A longitudinal ARIC study. Medicine (Baltimore). 2020;99(6):e18820. doi:10.1097/MD.0000000000018820
45. Park S, Kim S, Kim B, et al. Multivariate genomic analysis of 5 million people elucidates the genetic architecture of shared components of the metabolic syndrome. Nature Genetics. 2024;56(11):2380–2391. doi:10.1038/s41588-024-01933-1
46. Lee MK, Lee JH, Sohn SY, et al. Cumulative exposure to metabolic syndrome in a national population-based cohort of young adults and sex-specific risk for type 2 diabetes. Diabetology & Metabolic Syndrome. 2023;15(1):78. doi:10.1186/s13098-023-01030-z
47. Parekh N, Zizza C. Life course epidemiology in nutrition and chronic disease research: a timely discussion. Advances in Nutrition. 2013;4(5):551–553. doi:10.3945/an.113.004275
48. Wagner C, Carmeli C, Jackisch J, et al. Life course epidemiology and public health. The Lancet Public Health. 2024;9(4):e261–e269. doi:10.1016/S2468-2667(24)00018-5
Review
For citations:
Сhigir A.G. Metabolic Syndrome: Current Issues of Diagnosis, Epidemiology and Prevention Worldwide and in the Russian Federation. Epidemiology and Vaccinal Prevention. 2025;25(4):95-105. (In Russ.) https://doi.org/10.31631/2073-30462025-24-4-95-105
Views:
30
Email this article 